LIMERICK, Ireland, July 19, 2021 /CNW/ - kneat.com, inc.
(TSX-V: KSI) ("Kneat") is pleased to announce it has
signed a three-year Master Services Agreement to be the corporate
enterprise e-validation solution for one of the world's leading
healthcare brands.
This U.S.-headquartered company employs over ten thousand
people, has manufacturing facilities spanning the globe, and
products available in more than ninety countries. They design,
develop, manufacture, and market a range of pharmaceutical and
medical device products for multiple therapeutic areas. After an
extensive evaluation process, the company selected Kneat as their
corporate e-validation platform to scale to all sites across their
life sciences divisions.
The Master Services Agreement, which is effective immediately,
allows the company to scale Kneat across its business divisions.
The company's initial focus will be on scaling computer systems
validation digitization across all sites, followed closely by
facilities, utilities and equipment commissioning, qualification,
and verification processes. Their plan to leverage the Kneat
platform for all validation processes across their pharmaceutical
and medical device divisions represents a substantial opportunity
for expansion of Kneat's software over the coming years.
Implementation will commence in the coming weeks with an expected
go-live date in Q4 2021.
"We are delighted to be trusted as the corporate enterprise
solution for one of the world's most respected and diverse
healthcare brands", said Eddie Ryan,
Chief Executive Officer of Kneat. "This customer is known to be a
leader in innovation and quality, providing further evidence of
Kneat's product leadership."
This customer acquisition continues the trend of large, global
leaders selecting Kneat as their solution of choice. It also
contributes to the growing list of Kneat customers of all sizes
within biopharmaceuticals, medical devices, the life sciences
supply chain, and related industry verticals.
About Kneat
Kneat, a Canadian company with operational headquarters in
Limerick, Ireland, develops and
markets the next generation Kneat Gx SaaS platform. Multiple
business work processes can be configured on the platform from
equipment to computer system validation, through to quality
document management. Kneat's software allows users to author,
review, approve, execute testing online, manage any exceptions and
post approve final deliverables in a controlled FDA 21 CFR Part 11/
Eudralex Annex 11 compliant platform. Macro and micro report
dashboards enable powerful oversight into all systems, projects and
processes globally. Customer case studies are reporting
productivity improvements in excess of 100% and a higher data
integrity and compliance standard. For more information visit
www.kneat.com
Cautionary and Forward-Looking Statements
Except for the statements of historical fact contained herein,
certain information presented constitutes "forward-looking
information" within the meaning of applicable Canadian securities
laws. Such forward-looking information, includes, but is not
limited to, the relationship between Kneat and the customer,
Kneat's business development activities, the use and implementation
timelines of Kneat's software within the customer's validation
processes, the ability and intent of the customer to scale the use
of Kneat's software within the customer's organization and the
compliance of Kneat's platform under regulatory audit and
inspection. While such forward-looking statements are expressed by
Kneat, as stated in this release, in good faith and believed by
Kneat to have a reasonable basis, they are subject to important
risks and uncertainties. As a result of these risks and
uncertainties, the events predicted in these forward-looking
statements may differ materially from actual results or events.
These forward-looking statements are not guarantees of future
performance, given that they involve risks and uncertainties. Kneat
does not undertake any obligation to release publicly revisions to
any forward-looking statement, except as may be required under
applicable securities laws. Investors should not assume that any
lack of update to a previously issued forward-looking statement
constitutes a reaffirmation of that statement. Continued reliance
on forward-looking statements is at an investors' own risk.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this release.
SOURCE kneat.com, inc.
